0000899243-19-026599.txt : 20191104
0000899243-19-026599.hdr.sgml : 20191104
20191104175407
ACCESSION NUMBER: 0000899243-19-026599
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191104
FILED AS OF DATE: 20191104
DATE AS OF CHANGE: 20191104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ozawa Clare
CENTRAL INDEX KEY: 0001746742
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39112
FILM NUMBER: 191190938
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: (415) 801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
FORMER NAME:
FORMER CONFORMED NAME: Clare Ozawa
DATE OF NAME CHANGE: 20180716
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oyster Point Pharma, Inc.
CENTRAL INDEX KEY: 0001720725
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 811030955
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: (609) 382-9032
MAIL ADDRESS:
STREET 1: 202 CARNEGIE CENTER
STREET 2: SUITE 109
CITY: PRINCETON
STATE: NJ
ZIP: 08540
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-04
0
0001720725
Oyster Point Pharma, Inc.
OYST
0001746742
Ozawa Clare
C/O OYSTER POINT PHARMA, INC.
202 CARNEGIE CENTER, SUITE 109
PRINCETON
NJ
08540
1
0
0
0
Common Stock, par value $0.001 per share
2019-11-04
4
C
0
1941500
A
1941500
I
See footnotes
Common Stock, par value $0.001 per share
2019-11-04
4
C
0
495388
A
2436888
I
See footnotes
Common Stock, par value $0.001 per share
2019-11-04
4
P
0
125000
16.00
A
2561888
I
See footnotes
Common Stock, par value $0.001 per share
2019-11-04
4
C
0
566158
A
566158
I
See footnotes
Common Stock, par value $0.001 per share
2019-11-04
4
P
0
437500
16.00
A
1003658
I
See footnotes
Series A Convertible Preferred Stock
2019-11-04
4
C
0
1941500
D
Common Stock, par value $0.001 per share
1941500
0
I
See footnotes
Series B Convertible Preferred Stock
2019-11-04
4
C
0
495388
D
Common Stock, par value $0.001 per share
495388
0
I
See footnotes
Series B Convertible Preferred Stock
2019-11-04
4
C
0
566158
D
Common Stock, par value $0.001 per share
566158
0
I
See footnotes
These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
Shares held by Versant Vantage I, L.P. and may be deemed beneficially owned by the Reporting Person by reason of the Reporting Person being a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, L.P.
Shares held by Versant Venture Capital VI, L.P. ("Versant VI") and may be deemed beneficially owned by the Reporting Person as of November 1, 2019 upon becoming a managing member of Versant Ventures VI GP-GP, LLC, the general partner of Versant Ventures VI GP, L.P., the general partner of Versant VI.
The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/Jeffrey Nau, Attorney-in-fact
2019-11-04